FGKMX
Price
$104.54
Change
+$0.02 (+0.02%)
Updated
Sep 20 closing price
FTUCX
Price
$52.82
Change
+$0.21 (+0.40%)
Updated
Sep 20 closing price
Ad is loading...

FGKMX vs FTUCX

Header iconFGKMX vs FTUCX Comparison
Open Charts FGKMX vs FTUCXBanner chart's image
Fidelity Advisor Communication ServicesZ
Price$104.54
Change+$0.02 (+0.02%)
VolumeN/A
CapitalizationN/A
Fidelity Advisor Telecommunications C
Price$52.82
Change+$0.21 (+0.40%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FGKMX vs FTUCX Comparison Chart
Loading...
VS
FGKMX vs. FTUCX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGKMX is a StrongBuy and FTUCX is a StrongBuy.

FUNDAMENTALS
Fundamentals
FGKMX has more cash in the bank: 1.57B vs. FTUCX (196M). FTUCX pays higher dividends than FGKMX: FTUCX (1.66) vs FGKMX (0.00). FGKMX was incepted earlier than FTUCX: FGKMX (6 years) vs FTUCX (18 years). FGKMX is a more actively managed with annual turnover of: 45.00 vs. FTUCX (24.00). FGKMX (0) and FTUCX (0) have matching initial minimum investment requirements. FGKMX (27.38) and FTUCX (26.58) have marching annual gain over last year. FGKMX return over 5 years is better than : 60.04 vs. FTUCX (-7.79).
FGKMXFTUCXFGKMX / FTUCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence6 years18 years-
Gain YTD16.23716.47599%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/A500-
Net Assets1.57B196M799%
Annual Yield % from dividends0.001.66-
Returns for 1 year27.3826.58103%
Returns for 3 years3.13-18.26-17%
Returns for 5 years60.04-7.79-771%
Returns for 10 yearsN/A-9.32-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MSB21.240.40
+1.92%
Mesabi Trust
ALKS27.830.09
+0.32%
Alkermes plc
KVUE23.19-0.20
-0.86%
Kenvue
AGX88.39-0.80
-0.90%
Argan
QNCX0.74-0.02
-2.65%
Quince Therapeutics